Procter & Gamble stock: UBS maintains USD 172.00 target for Procter & Gamble stock

Published on 10/20/2026 at 17:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 sales were USD 87.00 billion. Procter & Gamble stock costs EUR 140.96 on October 20, 2026, up 0.56 percent versus Xetra close.

Analyst view and annual results

UBS maintained its USD 172.00 price target on October 16, 2026.
Fiscal 2026 net sales reached USD 87.00 billion, up 3.00 percent.
Procter & Gamble stock costs EUR 140.96 at Lang & Schwarz on October 20, 2026 at 5:08 p.m. CEST, 0.56 percent above the October 19, 2026 Xetra close of EUR 140.18.

Drogerieregal mit unbeschrifteten Verpackungen, Sinnbild für Procter & Gamble Konsumgüter — Fotorealistisches Drogerieregal zeigt unbeschriftete Verpackungen der The Procter & Gamble Company, ISIN US7427181091, Konsumgüterbranche Körperpflege, Illustration mit AI erstellt.

UBS maintained a Buy rating and a USD 172.00 price target for Procter & Gamble on October 16, 2026, according to Investing.com. The target stood 8.57 percent above the USD 158.42 NYSE price at 11:18 a.m. ET on October 20, 2026. At Lang & Schwarz, Procter & Gamble was trading at EUR 140.96 on October 20, 2026 at 5:08 p.m. CEST, up 0.56 percent versus the Xetra close of October 19, 2026 at EUR 140.18.

Fiscal 2026 sales reached USD 87.00 billion

Procter & Gamble's fiscal 2026 results showed net sales of USD 87.00 billion, up 3.00 percent, while operating cash flow reached USD 19.60 billion. These figures appear in the company's investor-relations summary for fiscal 2026, which also lists 1.00 percent organic sales growth and 1.00 percent core earnings-per-share growth, according to Procter & Gamble.

The annual result gives the analyst target a clear operating backdrop. UBS expects first-quarter fiscal 2027 earnings per share of USD 1.85, below its cited consensus estimate of USD 1.89, and said persistent inflation could push management toward the lower half of its fiscal 2027 earnings-per-share outlook, according to Investing.com.

Stock stays below its 52-week high

The NYSE price of USD 158.42 on October 20, 2026 sat within the USD 137.62 to USD 167.25 52-week range. The euro quote was 3.39 percent below the top of that range when measured in its own currency only through the corresponding USD price comparison. Procter & Gamble's market capitalization was USD 368.00 billion, and its price-to-earnings ratio was 23.94 on October 20, 2026.

Valuation and the next date

The next scheduled company event is the discussion of first-quarter fiscal 2027 results on October 22, 2026, at 8:30 a.m. ET. Procter & Gamble announced the webcast in a September 24, 2026 release carried by Procter & Gamble. The date is close enough to make the upcoming quarterly figures the next material test for the outlook.

Comparison with peers

Procter & Gamble: up 0.56 percent versus the October 19, 2026 Xetra close, price-to-earnings ratio 23.94, market capitalization USD 368.00 billion.

Colgate-Palmolive (NYSE, USD): up 1.09 percent on October 20, 2026, price-to-earnings ratio 37.20, market capitalization USD 74.80 billion.

Kimberly-Clark (NYSE, USD): up 1.63 percent on October 20, 2026, price-to-earnings ratio 18.23, market capitalization USD 35.60 billion.

Euro quote remains near the session high

The daily move was modest against the Xetra close, while the USD 172.00 target remained 8.57 percent above the NYSE price of USD 158.42 on October 20, 2026. At Lang & Schwarz, Procter & Gamble was trading at EUR 140.96 on October 20, 2026 at 5:08 p.m. CEST, up 0.56 percent versus the Xetra close of October 19, 2026 at EUR 140.18. The further course of trading is shown by the continuously updated real-time quote of Procter & Gamble stock.